(Q27023212)

language of work or name

1 reference

January 2012

1 reference

1 reference

25 Suppl 1

1 reference

PubMed

page(s)

S11-7

1 reference

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

PubMed

cites work

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2011.156

International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma

21 April 2017

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2011.156

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

21 April 2017

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2011.156

EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues

21 April 2017

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2011.156

The biology and treatment of EML4-ALK non-small cell lung cancer

21 April 2017

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2011.156

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

21 April 2017

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2011.156

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

21 April 2017

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.156

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK

21 April 2017

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.156

Clinical cancer genomics: how soon is now?

21 April 2017

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.156

Clinical significance of epidermal growth factor receptors in non-small cell lung cancer and a prognostic role for HER2 gene copy number in female patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.156

Clinically relevant characterization of lung adenocarcinoma subtypes based on cellular pathways: an international validation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.156

Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.156

Overview of gefitinib in non-small cell lung cancer: an Asian perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.156

Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.156

EGFR assays in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.156

EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.156

Genetic evolution of epidermal growth factor receptor in adenocarcinoma with a bronchioloalveolar carcinoma component.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.156

Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.156

EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.156

Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.156

Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.156

Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.156

EGFR FISH versus mutation: different tests, different end-points.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.156

Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.156

Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.156

Epidermal growth factor receptor mutation and p53 overexpression during the multistage progression of small adenocarcinoma of the lung.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.156

Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.156

EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.156

A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.156

Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.156

KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.156

Comprehensive histologic analysis of ALK-rearranged lung carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.156

Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.156

EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.156

The histopathology of BRAF-V600E-mutated lung adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.156

Prognostic and Therapeutic Implications of EGFR and KRAS Mutations in Resected Lung Adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.156

7 January 2021

A comparison of EGFR and KRAS status in primary lung carcinoma and matched metastases

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.156

7 January 2021

Heterogeneity of epidermal growth factor receptor mutations within a mixed adenocarcinoma lung nodule

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.156

7 January 2021

Micropapillary histology: a frequent morphology of mutation-associated lung adenocarcinoma?

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.156

7 January 2021

10.1038/MODPATHOL.2011.156

Identifiers

DOI

0 references

Dimensions Publication ID

1049809091

0 references

PubMed publication ID

22214966

1 reference